Table 4.
Safety of daptomycin treatment in overall EU-CORE population
| Safety parameters |
N = 6075 n (%) |
|
|---|---|---|
| Any AE | 866 | (14.3) |
| AE possibly related to daptomycin | 193 | (3.2) |
| AE leading to study drug discontinuation | 252 | (4.1) |
| Any SAE | 581 | (9.6) |
| SAE possibly related to daptomycin | 49 | (0.8) |
| SAE leading to study drug discontinuation | 175 | (2.9) |
| AEs occurring in >1% patients, n (%) | ||
| Multi-organ failure | 86 | (1.4) |
| Blood CPK increased | 76 | (1.3) |
| Septic shock | 75 | (1.2) |
| Sepsis | 73 | (1.2) |
AE adverse event, CPK creatine phosphokinase, SAE serious AE